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Abstract
Background: Low-penetrance genetic variants have been increasingly recognized to influence the risk of tumor
development. Risk variants for colorectal cancer (CRC) have been mapped to chromosome positions 8q23.3, 8q24, 9p24.1,
10p14, 11q23, 14q22.2, 15q13, 16q22.1, 18q21, 19q13.1 and 20p12.3. In particular, the 8q24 single nucleotide polymorphism
(SNP), rs6983267, has reproducibly been associated with the risk of developing CRC. As the CRC risk SNPs may also influence
disease outcome, thus in this study, we evaluated whether they influence patient survival.
Methodology/Principal Findings: DNA samples from 583 CRC patients enrolled in the prospective, North Carolina Cancer
Care Outcomes Research and Surveillance Consortium Study (NC CanCORS) were genotyped for 11 CRC susceptibility SNPs
at 6 CRC risk loci. Relationships between genotypes and patient survival were examined using Cox regression analysis. In
multivariate analysis, patients homozygous for the CRC risk allele of rs7013278 or rs7014346 (both at 8 q24) were only
nominally significant for poorer overall survival compared to patients homozygous for the protective allele (hazard
ratio = 2.20 and 1.96, respectively; P,0.05). None of these associations, however, remained statistically significant after
correction for multiple testing. The other nine susceptibility SNPs tested were not significantly associated with survival.
Conclusions/Significance: We did not find evidence of association of CRC risk variants with patient survival.
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Introduction
Colorectal cancer (CRC) is the second most common cause of
cancer-related death in the United States. Despite improvements
in treatment modalities, the 5-year survival rate for CRC patients
ranges from 10–90% [1]. This huge variation in clinical outcome
is due, in part, to the fact that CRC is a heterogeneous disease
comprising discrete subsets that evolve through multiple different
etiologies. Both germline and somatic genetic alterations can be
involved in the malignant transformation of normal colon cells.
Extensive investigations have identified somatic mutations in TP53
or KRAS that are involved in the progression of adenoma to CRC
[2–5]. For germline mutations, high-penetrance changes in
adenomatosis polyposis coli, mismatch repair, mothers against
decapentaplegic homolog 4, bone morphogenetic protein receptor
type IA and serine threonine kinase 11 genes have been reported
to be associated with increased CRC susceptibility in 5% of the
population [6] while the effects of combinations of low-penetrance
variants remains largely elusive.
The completion of the Human Genome Project and the
development of improved high-throughput genotyping techniques
permit large scale interrogation of the genome, resulting in a better
understanding of common polygenic disease. This progress has led
to the common disease, common variant hypothesis, which
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suggests that a number of allelic variants found in more than 1–5%
of the population genetically influences the susceptibility to
common heritable diseases [7]. In line with this model, candidate
gene analysis and multi-stage genome wide association studies
(GWAS) have identified numerous single nucleotide polymor-
phisms (SNPs) across several chromosomes that are associated with
an increased risk of CRC development [8–18]. In a case-control
study involving 1807 patients and 5511 controls, Haiman and
colleagues noted that rs6983267 on chromosome 8q24, a genomic
region that contains few genes, was significantly linked to a higher
predisposition of CRC in individuals of different ethnicities [10].
Several later reports confirmed rs6983267 as a low-penetrance risk
marker for CRC [9,12,13,16,17]. Given this consistent observa-
tion and the frequent amplification of this region in CRC [10],
further analysis of SNPs within this gene-poor area revealed a
second tightly linked variant, rs10505477, as well as three other
SNPs on 8q24, rs10808556, rs7014346 and rs7013278, as low-
penetrance variants that also influence carcinoma formation
[10,13,14,15,17].
Besides the SNPs on 8q24, Tomlinson et al identified
rs16892766 on 8q23.3 as an additional risk variant [15]. Likewise,
Zanke and colleagues found an association between rs719725 on
9p24 and CRC [17]. Subsequent investigation of this site by
Poynter et al showed that individuals with the A/A genotype had a
moderate increased risk of CRC compared to C/C individuals in
population-based but not clinic-based families [13]. On the 10p14
and 11q23 loci, rs10795668 and rs3802842 were respectively
shown to be related to disease occurrence [14,15]. In addition,
numerous other risk loci have been subsequently identified and
mapped to 14q22.2 (rs4444235, BMP4) [18], 15q13 (rs4779584,
rs10318, CRAC1) [11], 16q22.1 (rs9929218, CDH1) [18], 18q21
(rs4939827, rs12953717, rs4464148, SMAD7) [8], 19q13.1
(rs10411210, RPHN2) [18] and 20p112.3 (rs961253) [18].
Despite the increasing number of loci being identified to
influence the risk of CRC development, to date, only a few studies
have investigated the effects of these variants on disease outcome
[19–22]. The findings of these studies however remained
inconsistent on the relationship between these risk variants and
CRC survival. Therefore, in the present study, we examined the
prognostic significance of 11 CRC susceptibility SNPs at 6 CRC
risk loci (rs6983267, rs10505477, rs7013278, rs7014346,
rs719725, rs10795668, rs3802842, rs4779584, rs10318,
rs4464148 and rs4939827, Table S1), using 583 patients with
CRC from the prospective North Carolina (NC) Cancer Care
Outcomes Research and Surveillance Consortium Study (Can-
CORS).
Methods
Study Population and Follow-Up Information
The study design of CanCORS has been described previously
[23]. NC CanCORS assembled a prospective population-based
cohort in 33 county areas of NC, USA. In this study, DNA
samples from 583 eligible patients diagnosed with CRC between
April 2003 and January 2005 were retrospectively genotyped.
Patient demographics were obtained from a baseline patient
survey. Detailed clinical information on primary site of tumor,
American Joint Committee on Cancer (AJCC) stage and type of
treatment provided were obtained from review of medical records
and pathological reports of CRC diagnosis from the North
Carolina Central Cancer Registry by trained abstractors within 6
months following diagnosis. Patients were followed up for a
median of 3.5 years. Survival and mortality data was determined
from a three-year phone survey of participants or next-of kin and
further confirmed through ascertainment of death records through
the social security death index (SSDI) using patients’ social security
numbers. Mortality information or survival status was available for
all patients genotyped in this study through the SSDI. Disease-free
survival information was not available. This study was approved
by the Institutional Review Board of the University of NC (IRB
number: 04–08–60). Written informed consent was obtained from
each participant.
DNA Extraction and SNP Genotyping
Buffy coat was prepared from a blood sample collected from
each study participant. DNA was extracted from buffy coat using
Puregene kit (Qiagen, Valencia, CA, USA). In addition, DNA
samples comprising of 94 European-Americans, 93 Han Chinese
(Han people of Los Angeles) and 94 Mexican-Americans
(Mexican-American community of Los Angeles) from Coriell
(Coriell Institute for Medical Research, Camden, NJ, USA) as well
as 86 African-Americans as previously described [24], were also
used to confirm the reliability and reproducibility of the
genotyping performed. All DNA samples were genotyped for 11
CRC susceptibility SNPs at 6 CRC risk loci using TaqMan allelic
discrimination assays (Applied Biosystems, Foster City, CA, USA)
(Table S1). In a total volume of 20 mL, reactions consisted of 2 mL
of 10 ng/mL DNA, 0.5 mL of 20X TaqManH SNP genotyping
assays (Applied Biosystems), 10 mL of 2X TaqManH Universal
PCR Master Mix, No AmpErase UNG (Applied Biosystems) and
7.5 mL of water. PCR was performed with an initial denaturation
step at 95uC for 10 min followed by 50 cycles of denaturation at
92uC for 15 s and annealing with extension at 60uC for 1 min. All
PCR reactions were performed on a Bio-Rad Tetrad 2 Thermal
Cycler (Bio-Rad, Hercules, CA, USA). The fluorescence intensities
of the samples were measured before and after PCR using an
Applied Biosystems 7500 Real-Time PCR System (Applied
Biosystems). Data obtained was analyzed and genotypes assigned
using 7300 System SDS Software, version 1.4 (Applied Biosys-
tems). Genotype allocation was performed blinded to patients’
clinical data. Genotyping was successful in .96% of samples. For
the samples from the four additional populations, all genotypes
were in agreement with that reported in the Hapmap (www.
hapmap.org). No discordance in genotype or allele frequencies was
observed between the European-American or African-American
patient samples with the respective European-Americans or
African-Americans in the additional populations genotyped.
Statistical Analysis
All polymorphisms were examined for deviation from Hardy-
Weinberg equilibrium (HWE) using x2 test. Clinical and biological
variables were examined for associations with individual SNPs
using Fisher’s Exact Test. Univariate and multivariate survival
analyses were carried out using Cox regression analysis to evaluate
associations between genetic variants and overall survival.
Multivariate models were adjusted for age, ethnicity, gender,
disease stage, site of tumor and treatment administered. For each
SNP, the risk allele was defined as the allele previously established
in the literature to confer a risk of CRC while the other allele was
considered the protective allele. Homozygosity for the protective
allele served as a reference genotype for regression analysis and
was assigned a hazard ratio (HR) of 1.0. A P,0.05 was considered
significant. Multiple correction was performed using the conser-
vative Bonferroni method. All data was analyzed using SAS
statistical analysis software version 9 (SAS Institute Inc, Cary, NC,
USA).
CRC Risk Variants Don’t Influence Clinical Outcome
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Results
Patient Characteristics
Table 1 summarizes the baseline characteristics of patients in
this study. The median age of patients was 65.0 years old and
47.9% were female. Among the 583 patients, 81.0% were
European-Americans and 19.0% were African-Americans. At
the time of diagnosis, the proportions of study participants
classified to AJCC stages 1, 2, 3 and 4 were 27.6%, 27.4%,
28.3% and 11.7% respectively. In this cohort, the proportion of
patients with colon cancer or rectal cancer was comparable. The
majority of patients (98.3%) received surgical treatment while
chemotherapy was administered to 50.9% of the study population.
Low-Penetrance CRC Susceptibility Genotypes
The distribution of genotypes in this patient cohort is presented in
Table S2. For this group of patients, no deviation from HWE was
detected among European- or African-American patients for any of
the SNPs. The allele frequencies for all SNPs were similar to
frequencies of European- (CEU) and African-American populations
(ASW) reported in HapMap (www.hapmap.org). Genotype distri-
butions varied between European- and African-American patients
for all SNPs (P,0.05) except rs7014346 and rs3802842 (Table S2).
Relationships Between Low-Penetrance CRC
Susceptibility SNPs and Clinicopathological Features of
CRC Patients
No significant differences were observed between the SNPs with
gender, tumor site, surgical intervention or chemotherapy
administration (Table S2). For age of CRC diagnosis, apparent
differences in genotype distribution were only found for
rs10795668 (P = 0.005; Table S2). It was observed that the
prevalence of the A/A genotype for this SNP decreases in patients
older than 50 years. In addition, stage of disease was significantly
related to rs4464148 and rs4939827 genotypes (P,0.05; Table
S2). C and T alleles, the risk allele for rs4464148 and rs4939827
respectively, were shown previously to be associated with an
increased risk for CRC [8,21]. Surprisingly in the present study,
more patients homozygous for the risk allele for both SNPs
presented with earlier stage cancer (stages 1–2) at the time of
diagnosis, suggesting that these alleles are protective (Table S2).
Relationships Between Low-Penetrance CRC
Susceptibility SNPs and Overall Survival
To test whether the germline variants underlie differences in
overall survival in CRC patients, we performed both univariate
and multivariate survival analyses. In univariate analysis, a
significant difference in survival was only observed in patients
with the A/C genotype compared to the A/A genotype for
rs3802842 (P,0.05; Table 2). This difference was not significant
in a multivariate model (P.0.05; Table 2). In multivariate
analysis, patients carrying two risk alleles (T/T) for rs7013278
had reduced survival compared with patients homozygous for
protective allele (C/C) (HR = 2.20; 95% CI = 1.24–3.91; P = 0.01;
Table 2). Likewise, patients homozygous for the CRC risk allele of
rs7014346, A/A, showed inferior overall survival to G/G patients
(HR = 1.96; 95% CI = 1.08–3.52; P = 0.03; Table 2). The mod-
erate level of significance for these two SNPs was not maintained
upon correction for multiple testing. No additional significant
association was observed between the rest of the SNPs studied and
survival (Table 2).
Discussion
The present study was performed to examine the prognostic
significance of 11 common, low-penetrance genetic variants at 6
CRC loci that have been previously reported to predispose
individuals to CRC [8–17]. Although we found marginal
significance between two SNPs, rs7013278 and rs7014346
(HR = 2.20, P = 0.01 and HR = 1.96, P = 0.03 respectively), with
inferior CRC survival by multivariate regression analysis, none of
these variants showed study-wide association with survival after
correction for multiple testing. It therefore highlighted that these
known CRC risk variants, do not play a role in influencing CRC
mortality, which is in agreement with the findings from three
earlier studies [19–21].
So far, several prior studies have investigated the association
between CRC susceptibility variants with disease progression and
survival. Gruber and colleagues were the first to report no
correlation between rs10505477 with CRC survival in a predom-
inantly Jewish population [19]. In this study, a HR of 1.09
(CI = 0.89–1.32) was found between carriers of risk allele versus
non carriers [19] Subsequently, Cicek and colleagues evaluated
the influence of 5 other low- penetrance CRC risk markers
(rs6983267, rs13254738, rs16901979, rs1447295, DG8S737) on
the survival of 460 cases of stages II and III, Caucasian, CRC
patients who were the participants of a phase III adjuvant therapy
study [20]. While they observed a trend of decreased survival rate
with the presence of the rare risk variants (HR for
rs6983267 = 1.00, CI = 0.79–1.27; HR for rs13254738 = 1.14,
CI = 0.91–1.43; HR for rs16901979 = 1.34, CI = 0.86–2.09; HR
for rs1447295 = 1.11, CI = 0.79–1.55; HR for DG8S737 = 1.57,
CI = 0.85–2.90) using a log additive model, none of the
Table 1. Demographic, Histopathological and Clinical




Age, years Median (range) 65.0 (26.0–93.0)
Gender Male 304 (52.1)
Female 279 (47.9)
Ethnicity European-American 472 (81.0)
African-American 111 (19.0)





Tumor Site Colon 261 (44.8)
Rectum 241 (41.3)
Missing 81 (13.9)









CRC Risk Variants Don’t Influence Clinical Outcome
PLoS ONE | www.plosone.org 3 July 2012 | Volume 7 | Issue 7 | e41954
associations were statistically significant [20]. In a later study by
Tenesa et al, no association was found between 10 risk variants
and all-cause or CRC-specific mortality after adjustment for AJCC
stage, age and sex in 2838 AJCC stages I-IV CRC patients of
Scottish Ancestry [21]. Likewise, we observed a similar lacked of
correlation between rs10505477 (HR using multivariate analy-
sis = 1.38, CI = 0.74–2.55) with survival which is in agreement
with the finding by Gruber et al (HR = 1.09, CI = 0.89–1.32) [19].
For rs6983267, there was again no association with CRC survival
in our study (HR using multivariate analysis = 1.35, CI = 0.73–
2.51). The HR for this SNP is in similar direction and again in
agreement with previous reports by Cicek et al (HR = 1.00,
CI = 0.79–1.27) and Tenesa et al (HR = 1.03, CI = 0.94–1.13)
[20,21]. Furthermore, for 4 other SNPs (rs10795668, rs3802842,
rs4779584 and rs4939827), the HRs obtained by Tenesa and
colleagues were 0.98 (CI = 0.90–1.08), 0.93 (CI = 0.85–1.02), 0.95
(CI = 0.85–1.06) and 1.05 (CI = 0.96–1.15) respectively [21]. This
result is in congruent with our study with HRs for rs10795668,
rs3802842, rs4779584 and rs4939827 to be 0.82 (CI = 0.37–1.83),
1.03 (CI = 0.52–2.03), 1.01 (CI = 0.46–2.22) and 0.81 (CI = 0.45–
1.48) respectively, with the range of CI values for these SNPs
overlapping between the two studies. This data thus reinforce the
lack of evidence for the involvement of these variants with CRC
outcome. In a recent study by Xing et al, the influence of 8 GWAS
associated SNPs with CRC recurrence and survival was investi-
gated in 465 Han Chinese CRC patients [22]. Two SNPs,
rs4779584 (HR = 0.33, CI = 0.15–0.72 for homozygous carriers of
the wild type allele (T), which is also the risk allele in GWAS,
versus those who are homozygous or heterozygous carriers of the
variant allele (C), the protective allele in previous GWAS) and
rs10795668 (HR = 0.55, CI = 0.30–1.00 for homozygous carriers
of the wild type allele (G), which is the protective allele in previous
GWAS, versus those who are homozygous or heterozygous
carriers of the variant allele (A), the risk allele in previous GWAS),
were significantly associated with reduced risk of death and tumor
recurrence respectively using a dominant genetic model [22]. For
rs4779584, the result of this study (HR = 1.01, CI = 0.46–2.22) and
that of Tenesa et al (HR = 0.95, CI = 0.85–1.06) [21] showed no
significant influence of the risk allele of this SNP with CRC
survival. This deviates from the findings of Xing et al [22]. A
plausible explanation for this deviation is a much higher frequency
of the risk allele among the Han Chinese compared to the
population in this study and that of Tenesa and colleagues [21],
which were predominately of European ancestry. While the allele
frequencies of rs4779584 in the Han Chinese CRC patients were
not directly reported in the paper by Xing et al [22], a calculation
of the allele frequencies of this population based on the genotype
of patients presented showed that the calculated allele frequencies
(C = 0.19 and T = 0.81) were congruent with that from the
Chinese populations in the Hapmap (CHB: C = 0.18 and
T = 0.82; CHD: C = 0.16 and T = 0.84) and the Han Chinese
population that we have previously genotyped (C = 0.17 and
T = 0.83) as part of the four additional populations used for
genotyping control. Based on the data from Hapmap and our data
of the four additional populations genotyped (data not shown), the
allele frequency for the risk allele (T) of rs4779584 was highest in
the Han Chinese, followed by African-American and lastly
European-American. For rs10795668, HR for overall survival in
our study and that by Tenesa et al [21] were 0.82 (CI = 0.37–1.83)
and 0.98 (CI = 0.90–1.08) respectively. This divergence in study
results to that of Xing et al is likely attributed to methodological
differences between studies rather than due to differences in allele
frequencies as the study by Xing et al [22] evaluated CRC








Ratio 95% CI P
Hazard
Ratio 95% CI P
rs6983267
T/T G 1.00 – – 1.00 – –
G/T 0.85 0.51–1.41 0.53 1.07 0.59–1.93 0.83
G/G 1.17 0.71–1.92 0.54 1.35 0.73–2.51 0.35
rs10505477
G/G A 1.00 – – 1.00 – –
A/G 0.90 0.55–1.48 0.68 1.14 0.64–2.06 0.65
A/A 1.21 0.74–1.98 0.46 1.38 0.74–2.55 0.31
rs7013278
C/C T 1.00 – – 1.00 – –
C/T 0.94 0.63–1.40 0.76 1.06 0.66–1.71 0.81
T/T 1.55 0.94–2.56 0.08 2.20 1.24–3.91 0.01*
rs7014346
G/G A 1.00 – – 1.00 – –
A/G 0.89 0.60–1.31 0.56 1.04 0.67–1.64 0.84
A/A 1.33 0.78–2.27 0.29 1.96 1.08–3.52 0.03*
rs719725
C/C A 1.00 – – 1.00 – –
A/C 1.29 0.69–2.39 0.43 0.93 0.47–1.86 0.84
A/A 1.07 0.57–2.01 0.84 0.80 0.39–1.62 0.53
rs10795668
G/G A 1.00 – – 1.00 – –
A/G 0.79 0.54–1.16 0.23 0.82 0.51–1.31 0.40
A/A 0.54 0.25–1.17 0.11 0.82 0.37–1.83 0.62
rs3802842
A/A C 1.00 – – 1.00 – –
A/C 1.53 1.05–2.23 0.03* 1.25 0.80–1.93 0.33
C/C 0.95 0.50–1.79 0.88 1.03 0.52–2.03 0.94
rs10318
C/C T 1.00 – – 1.00 – –
C/T 1.10 0.74–1.64 0.63 1.20 0.73–1.90 0.50
T/T 0.50 0.12–2.03 0.33 0.62 0.15–2.55 0.50
rs4779584
C/C T 1.00 – – 1.00 – –
C/T 0.92 0.63–1.34 0.65 0.72 0.45–1.14 0.16
T/T 1.02 0.52–1.98 0.96 1.01 0.46–2.22 0.98
rs4464148
T/T C 1.00 – – 1.00 – –
C/T 0.78 0.54–1.15 0.21 0.74 0.48–1.16 0.19
C/C 0.95 0.50–1.80 0.87 1.39 0.67–2.90 0.38
rs4939827
C/C T 1.00 – – 1.00 – –
C/T 0.90 0.60–1.34 0.59 0.82 0.52–1.30 0.40
T/T 0.82 0.50–1.36 0.44 0.81 0.45–1.48 0.50
#Potential confounding variables such as age, gender, ethnicity, stage, and
treatment received were included in multivariate modeling
*Statistically significant at P,0.05.
doi:10.1371/journal.pone.0041954.t002
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recurrence while our study and that by Tenesa et al [21] evaluated
overall survival and overall mortality respectively.
This inconsistency in findings between reported studies is not
surprising as the mechanisms by which these variants alter the risk
of CRC is not fully understood and it is still unclear how they
might influence tumor progression and patient survival. Currently,
the potential functional effects of these SNPs have been most
widely investigated for the variants at the 8 q24 gene locus. Since
this locus is not known to encode for any gene, it was thus
conceived that the variants found here may either lie within
promoters or enhancer elements that can affect the transcription of
genes outside this locus [10]. However, in a study using the UCSC
Browser and VISTA Enhancer database, rs7013278 and
rs7014346, which showed marginal significance in our study prior
to Bonferroni correction, were not found in segments containing
putative enhancers or in predicted regions of regulatory potential
[25]. On the other hand, rs6983267 was found to lie within a
putative enhancer element that binds TCF4, a transcription factor
that interacts with ß-catenin to activate the transcription of Wnt
target genes, which are activated in most CRCs [26,27].
Additionally, some reports have shown that rs6983267 has a long
range physical interaction with a promoter region of MYC in
colorectal cancer cell lines [26,28]. Despite this, no association
between the risk allele of rs6983267 and MYC expression levels
has been found in normal and cancerous colon tissues [17,26,27].
Therefore, the functional consequence of rs6983267 remains
uncertain.
For rs10795668 at 10 p14, rs3802842 at 11 q23 and rs 4779584
at 15 q13, a systematic search by Niittymaki and colleagues failed
to show any association of these SNPs with predicted enhancer or
regulatory elements [29]. Further investigation using tumor
samples again showed a lack of allelic imbalance between the
risk allele of these SNPs with CRC, prompting the authors to
conclude that these risk variants were unlikely somatically selected
for neoplastic progression [29]. While the functional effects of
these susceptibility SNPs remain to be further validated, the results
of these functional studies to date support our finding that the
majority of low-penetrance CRC variants are involved in initiation
rather than progression of CRC.
The strength of this study is that the patients were drawn at
random from 33 county areas in central and eastern NC. These
regions include urban and rural areas and as such the subjects are
diverse with respect to race and socioeconomic status. They are
therefore more representative of a true CRC population sample
compared with other studies that only include patients from a few
institutions and thus have highly selected populations.
There are however some limitations in our study. Firstly, the
limited sample sizes of certain stages prevented a more detailed
subgroup analysis. At such, it is possible that associations restricted
to patients from certain stages may have been missed. Secondly,
the median follow-up period of 3.5 years may be too short
especially for patients with stages I and II disease. This could have
in turn resulted in a lower event rate when data from all four stages
of patients were analysed together and hence led to the marginal
association observed. Thirdly, information on disease free survival
data which may be a better prognostic measure compared to
overall survival is not available in our study. Fourthly, while we
made a rigorous effort to take into consideration important clinical
variables such as age, sex, ethnicity, stage of disease, site of tumor
and type of treatment that may influence CRC survival in our data
analysis, we however did not have information on patients’
mismatch repair status. This may have led to the combination of
different types of CRC in the same group for analysis, thereby
biasing the hazard estimates obtained. Lastly, the sample size of
this study is moderate. This may make it underpowered to detect
the association of the genetic variants with survival outcomes for
two SNPs (rs719725 and rs10318) due to low allele frequencies in
our population or for SNPs with small effects on survival. Thus, for
rs719725 and rs10318, the results for these SNPs should be
interpreted cautiously. Nonetheless, the results of this study will
augment the findings of earlier studies, allowing for future meta-
analysis that can further improve our understanding of the effects
of these rare variants on CRC progression.
In conclusion, we observed no association between 11 CRC
susceptibility variants at 6 CRC risk loci with disease outcome in
our study population, suggesting little influence of these SNPs on
CRC progression.
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